Medtronic Inc. (NYSE:MDT) said the results of a clinical trial for its new remote monitoring network indicate that the system reduces healthcare costs.
The study showed that monitoring of implantable cardiac device patients with the Medtronic’s CareLink network and CareAlert notification system cuts down on healthcare utilization costs when compared to in-office follow-up appointments, according to the company.
"[R]emote monitoring reduces the time from a clinically-actionable event to a clinical decision by 79 percent, reduces average length of hospital stay for cardiovascular reasons by 18 percent (0.7 days), and provides estimated costs savings of $1,793 per admission," the company said in a prepared release.
The results of the clinical trial, entitled "CONNECT," were published today in the Journal of the American College of Cardiology.
Here’s a roundup of recent clinical trial and scientific study news:
- NanoLogix touts MRSA-test results
NanoLogix Inc. (OTC:NNLX) announced preliminary results of MRSA (Methicillin-resistant Staphylococcus aureus) testing at the University of Texas Health Science Center – Houston. Dr. Jonathan Faro found NanoLogix technology is able to deliver results for MRSA in 6 hours, as opposed to conventional culture-based testing wait times of 24 to 48 hours. Faro is lead researcher in an ongoing Group B Streptococcus clinical trial using NanoLogix test kits at UTHSC.
- Study on blood vessel growth with stem cells presented at CRT conference
At Cardiovascular Research Technologies 2011 (CRT) conference, Minnesota Heart Institute (MHI) director of research Dr. Tim Henry presented the latest data from a variety of ongoing efforts to use adult stem cells to grow new blood vessels or new myocardium. MHI is part of the Cardiovascular Cell Therapy Research Network funded by the National Heart, Lung, and Blood Institute (NHLBI), reports Heartwire.
- Alliqua closes in on transdermal pain patch
Alliqua Inc. (OTC:ALQA) announced the successful completion of its initial in vitro permeation study for its transdermal pain patch project. These results represent a milestone in the development of a transdermal pain patch, according to the company. Alliqua previously announced the successful completion of its dissolution study. Alliqua believes that the results provide it with options to pursue a 505(b)(2) type of a New Drug Application (NDA), along with a generic route for an Abbreviated New Drug Application (ANDA) with the Food & Drug Administration.
- Osiris completes enrollment of stem cell trial for heart attack treatment
Osiris Therapeutics Inc. (NSDQ:OSIR) completed enrollment in a Phase 2 clinical trial evaluating Prochymal (remestemcel-L), an adult mesenchymal stem cell therapy, in patients experiencing their first heart attack. The double-blind, placebo-controlled trial enrolled a total of 220 patients from 33 leading clinical centers in the United States and Canada. In 2009, Osiris completed a Phase 1 double-blind, placebo-controlled study in 53 patients that demonstrated the safety of Prochymal in cardiac patients suffering from their first heart attack. Additionally, treatment with Prochymal significantly improved cardiac function, patient global assessment and reduced cardiac arrhythmias (irregular heartbeat) when compared to placebo.